Based on our laboratory ARMS PCR data (Table S1) and WES analysis, we can conclude that the percentages of EGFR mutations in the non-NEC (all ADC) and NEC (all SCLC) components were 42.9% (9/21), 42.9% (9/21), respectively. This evidence concerns the gene EGFR and neuroendocrine carcinoma.